

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Experimental Aristolochic Acid Nephropathy

Baudoux, Thomas; Jadot, Inès; Declèves, Anne Emilie; Antoine, Marie Hélène; Colet, Jean Marie; Botton, Olivia; De Prez, Eric; Pozdzik, Agnieszka; Husson, Cécile; Caron, Nathalie; Nortier, Joëlle L.

Published in:
Frontiers in Medicine

DOI:
[10.3389/fmed.2022.822870](https://doi.org/10.3389/fmed.2022.822870)

Publication date:
2022

Document Version
Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (HARVARD):

Baudoux, T, Jadot, I, Declèves, AE, Antoine, MH, Colet, JM, Botton, O, De Prez, E, Pozdzik, A, Husson, C, Caron, N & Nortier, JL 2022, 'Experimental Aristolochic Acid Nephropathy: A Relevant Model to Study AKI-to-CKD Transition', *Frontiers in Medicine*, vol. 9, 822870. <https://doi.org/10.3389/fmed.2022.822870>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Experimental Aristolochic Acid Nephropathy: A Relevant Model to Study AKI-to-CKD Transition

Thomas Baudoux^{1†}, Inès Jadot^{2†}, Anne-Emilie Declèves³, Marie-Hélène Antoine¹, Jean-Marie Colet⁴, Olivia Botton², Eric De Prez¹, Agnieszka Pozdzik¹, Cécile Husson¹, Nathalie Caron² and Joëlle L. Nortier^{1*}

OPEN ACCESS

Edited by:

Thierry Hauet,
University of Poitiers, France

Reviewed by:

Tarak Srivastava,
Children's Mercy Hospital,
United States

*Correspondence:

Joëlle L. Nortier
joelle.nortier@chu-brugmann.be;
joelle.nortier@ulb.be

[†]These authors have contributed
equally to this work and share first
authorship

Specialty section:

This article was submitted to
Nephrology,
a section of the journal
Frontiers in Medicine

Received: 26 November 2021

Accepted: 24 March 2022

Published: 04 May 2022

Citation:

Baudoux T, Jadot I, Declèves AE,
Antoin MH, Colet JM, Botton O,
De Prez E, Pozdzik A, Husson C,
Caron N and Nortier JL (2022)
Experimental Aristolochic Acid
Nephropathy: A Relevant Model to
Study AKI-to-CKD Transition.
Front. Med. 9:822870.
doi: 10.3389/fmed.2022.822870

¹Laboratory of Experimental Nephrology, Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium,

²Molecular Physiology Research Unit (URPhyM), Namur Research Institute for Life Sciences (NARILIS), University of Namur (UNamur), Namur, Belgium, ³Laboratory of Molecular Biology, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons (UMONS), Mons, Belgium, ⁴Department of Human Biology & Toxicology, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons (UMONS), Mons, Belgium

Aristolochic acid nephropathy (AAN) is a progressive tubulointerstitial nephritis caused by the intake of aristolochic acids (AA) contained in Chinese herbal remedies or contaminated food. AAN is characterized by tubular atrophy and interstitial fibrosis, characterizing advanced kidney disease. It is established that sustained or recurrent acute kidney injury (AKI) episodes contribute to the progression of CKD. Therefore, the study of underlying mechanisms of AA-induced nephrotoxicity could be useful in understanding the complex AKI-to-CKD transition. We developed a translational approach of AKI-to-CKD transition by reproducing human AAN in rodent models. Indeed, in such models, an early phase of acute tubular necrosis was rapidly followed by a massive interstitial recruitment of activated monocytes/macrophages followed by cytotoxic T lymphocytes, resulting in a transient AKI episode. A later chronic phase was then observed with progressive tubular atrophy related to dedifferentiation and necrosis of tubular epithelial cells. The accumulation of vimentin and α SMA-positive cells expressing TGF β in interstitial areas suggested an increase in resident fibroblasts and their activation into myofibroblasts resulting in collagen deposition and CKD. In addition, we identified 4 major actors in the AKI-to-CKD transition: (1) the tubular epithelial cells, (2) the endothelial cells of the interstitial capillary network, (3) the inflammatory infiltrate, and (4) the myofibroblasts. This review provides the most comprehensive and informative data we were able to collect and examines the pending questions.

Keywords: aristolochic acid nephropathy, AKI-to-CKD transition, animal models, renal fibrosis, nephrotoxicants, aristolochic acids

INTRODUCTION

For a long time, the common belief was that the long-term outcome of patients recovering from acute kidney injury (AKI) was benign. However, this previous paradigm has been progressively challenged as several epidemiological studies demonstrated that AKI significantly increases the risk of chronic kidney disease (CKD) onset (1–8). Indeed, severe or repeated AKI episodes initiate an exaggerated recovery process leading ultimately to rarefaction and sclerosis of glomeruli, atrophy and dilation of tubules, tubulointerstitial fibrosis and peritubular capillaries rarefaction, all being characteristic of CKD (9). All these epidemiological and clinical reports have raised the urgent need to determine whether the progression of this process could be stopped or at least delayed. In this regard, animal models represent a relevant tool to investigate the pathophysiological link between AKI and CKD and to assess therapeutic strategies (10). In addition to the classical models of ischemic reperfusion injury (IRI) and unilateral ureteral obstruction (UUO), experimental nephrotoxic approaches represent an attractive alternative.


Human aristolochic acid nephropathy (AAN) was formerly known as “Chinese herb nephropathy.” This tubulointerstitial nephritis was first reported in Belgian women after ingestion of herbal slimming remedies containing aristolochic acids (AA) (11). At this time, clinicians were amazed by the prominent interstitial fibrosis with a typical corticomedullary gradient and the tubular atrophy characterizing this nephrotoxicity (12). Later, AA metabolism was found to lead to DNA adducts formation (13). These specific AA-DNA adducts are known to induce carcinogenesis and mutagenesis by activation of *H-ras* proto-oncogene in rats and by *p53* gene mutation in humans finally leading to uretero-vesical cancers (14–18). Beside the Belgian outbreak, these nitrophenanthrene derivatives were also found responsible for thousands of cases of the so-called Balkan endemic nephropathy (19, 20). Finally, in China and Taiwan where traditional herbal medicines are still widely used, more than 300 cases have been described but this number is certainly underestimated as billions of Chinese and Taiwanese’s patients could have been exposed to AA (21–24). Human AAN has been reproduced in several animal models including rabbits, mice and rats (25–29). Interestingly, a biphasic evolution of the tubulointerstitial lesions was demonstrated in our male Wistar rat model and in our mice models (26, 27, 30). The acute phase (several days following the beginning of AA exposure) is characterized by a necrosis of the proximal tubular epithelial cells (PTEC) concomitantly to a rise of plasma creatinine. This phase is rapidly followed by an inflammatory infiltrate along with a normalization of the biological parameters, reflecting an attempt of PTEC regeneration. Following the acute phase, interstitial fibrosis and tubular atrophy were the main hallmarks of the later chronic phase (already several days after starting AA exposure and persisting after cessation of AA intoxication). Regarding the marked interstitial fibrosis characterizing AAN, these models are of particular interest in order to study the AKI-to-CKD transition and the respective role of the different actors involved in this process.

MAJOR CELLULAR MECHANISMS UNDERLYING AKI-TO-CKD PROGRESSION AND TRANSLATION TO AAN MODELS

Clearly, mechanisms linking AKI to CKD are in part universal and independent of the initial aggression. Understanding the respective roles of the actors involved in the AKI-to-CKD transition is essential to develop prevention strategies. In this regard, Eddy proposed four pivotal cellular responses in the disease progression: (1) the response of tubular epithelial cells to the aggression; (2) the loss of endothelial integrity; (3) the interstitial inflammatory response and (4) the appearance of a new interstitial cell population, the myofibroblasts (Figure 1) (31). The following sections are dedicated to each of these major processes and their translation to rodent models of AAN.

The Proximal Tubular Epithelial Cells

The selective toxicity of AA for PTEC has rapidly been highlighted (26). In our Wistar rat model, structural and functional parameters of proximal tubular injury were longitudinally investigated: (1) the acute tubular necrosis histologically delineated to the S3 segment (from day 1 to day 5 after the beginning of AA subcutaneous exposure) was found concomitant to a dramatic urinary increase in low molecular weight proteins, reflecting the loss of reabsorptive capacity by the apical brush border of the tubular epithelium; (2) consecutively






FIGURE 2 | Time course of histological alterations in experimental AAN. Representative photographs of hemalun, Luxol fast blue and Periodic Acid Schiff stained kidney sections [x200 (A–D), x400 (E–H), and x1000 (I–L)] from CTL mice and mice intoxicated with AA (aristolochic acid I, Sigma-Aldrich, St. Louis, MO, USA) during 4 consecutive days. Mice were sacrificed 5, 10, and 20 days after first day of AA treatment. Necrotic tubules with cell debris in tubular lumen are visible in mice treated with AA at days 5 and 10 and cystic tubules are visible in mice at days 10 and 20.

to interstitial infiltration by inflammatory cells, areas of non-regenerative tubular necrosis were rapidly replaced by severe tubular atrophy and were surrounded by interstitial fibrosis. In addition, in the rat Wistar model, induction of active caspase-3 in the PTEC demonstrated the contribution of apoptosis in tubular atrophy (27). This biphasic evolution was reproduced in our mouse models (Figure 2). The PTEC targeting by AA suggested the involvement of specific molecular mechanisms that could be responsible for the accumulation of the toxin in these cells. This hypothesis has been confirmed *in vitro* (32, 33) and *in vivo* (28, 34) by several studies reporting a critical role of the organic anion transporter (OAT) family in AA uptake into the PTEC. Specifically, we demonstrated that in AA-treated mice, probenecid treatment reduced tubular necrosis, lymphocytic infiltrate, tubular atrophy as well as fibrosis by blocking AA entry into PTEC as attested by the reduction of DNA-adducts formation (28).

Moreover, it has been pointed out that the formation of AA-DNA adducts is not necessarily associated to AA nephrotoxicity (35, 36). The formation of those adducts is not the only source of cytotoxicity. Indeed, AA-induced cytotoxicity could also be linked to the release of Ca^{2+} from the endoplasmic reticulum (ER) that causes ER and mitochondrial stress resulting in caspases activation and apoptosis (37–39). Furthermore, we and others reported that AA led to an increase in oxidative stress that contributed to DNA damage and cell cycle arrest

in experimental studies (27, 40–44). In this regard, Bonventre demonstrated that following AA-induced AKI, PTEC stop their cell cycle in the G2/M phase. This arrest is considered as a protective mechanism as it could help to repair DNA lesions (44). However, this mechanism has also been found to be associated with an excessive production of transforming growth factor β (TGF β) and connective tissue growth factor (CTGF) thereby promoting fibrosis.

The cell death process (necrosis, apoptosis or autophagy) may also influence the outcome of AKI. Indeed, PTEC necrosis yields pro-inflammatory factors that act as dangers associated molecular patterns (DAMPs). After linking with Toll like receptors (TLR), DAMPs lead to an activation of the innate immune system and a pro-inflammatory environment (45). On the other hand, some authors postulate that apoptosis does not constitute a maladaptive process but is rather a way to eliminate the damaged cells without the release of cellular debris. This hypothesis is supported by the study of Bonventre who demonstrated reduced apoptosis in the AAN model as compared to other AKI models such as IRI. AAN animals also displayed more extensive fibrosis, suggesting that apoptosis constitutes an adaptive mechanism and that cells undergoing cell cycle arrest instead of progressing to apoptosis exert profibrogenic effects (46, 47). However, the role of p53 inhibition on chronic lesions remains controversial: some authors described a worsening of the lesions (48) as others suggested the opposite (49). Recently,

the impact of p53 on AAI-induced nephrotoxicity and DNA damage was investigated *in vivo* using *Trp53*(+/+), *Trp53*(+/-), and *Trp53*(-/-) mice (50). Interestingly, renal injury was more severe in AAI-treated *Trp53*(-/-) mice relative to *Trp53*(+/+) and *Trp53*(+/-) mice (50).

Finally, we performed an analysis of urine metabolites from rats intoxicated with AA by the use of NMR spectrometry. A significant reduction in Krebs cycle components (α -cetoglutarate, succinate, citrate) was found, suggesting a mitochondrial injury (51).

Finally, PTEC could also contribute to interstitial fibrosis through a complex phenomenon called epithelial-to-mesenchymal transformation (EMT) (see Section The Myofibroblasts) (27, 52).

The Endothelial Cell Injury

The preservation of endothelium structure and function constitutes a key element of renal function. In this regard, numerous kidney injury models have demonstrated a sustained renal vasoconstriction and a rarefaction of the peritubular capillaries (PC) around injured tubules as prominent features of kidney disease (53) ultimately leading to renal hypoxia thereby promoting fibrosis and progression to CKD (54–57).

Following injury, renal endothelial cells switch from a quiescent to an activated state, leading to an imbalance in the production of vasoactive substances inducing a vasoconstrictive environment and a reduced blood flow. Specifically, a decreased bioavailability of nitric oxide (NO) was described as a characteristic feature of kidney disease (58).

Moreover, a long-term consequence of AKI is a PC rarefaction that is also considered as a hallmark of CKD (31, 59, 60). This PC rarefaction is thought to be due to an anti-angiogenic environment (60) and to the loss of endothelial cells as well as pericytes that transdifferentiate into myofibroblasts (see section Conclusions). It also emphasizes the fact that endothelial cells, unlike tubular cells, fail to regenerate (61, 62).

Only few studies have addressed the involvement of the vascular network in AAN pathophysiology. In this regard, Depierreux et al. were the first to describe a thickening of the walls of interlobular and afferent arterioles due to swelling of endothelial cells in human kidney biopsies from Belgian AAN patients. They proposed that primary lesions could occur in the vessel walls, then inducing tubular destruction (12). Since then, other investigators demonstrated a dramatic decrease in PC, in particular in the fibrotic areas in human renal tissue samples as well as in experimental models (63, 64). In a rat model of AAN, the reduction of PC network was associated to a decreased expression of vascular endothelial growth factor (VEGF) and to an increased expression of hypoxia inducible factor 1 α (HIF-1 α), thereby suggesting that ischemia and hypoxia are critical processes contributing to AAN progression (63). Similar data were also reported by Wen et al. in a rat model of AAN. Interestingly, they also described an imbalance between the vasoactive factors with a reduced NO production occurring along with an increase in mRNA and protein expression of endothelin (ET) (65). Such imbalance between vasoactive substances was also investigated in our lab in a mouse model of AAN. In

our hands, renal NO bioavailability was reduced following AA intoxication not only during the acute phase (66) but also during the progression to the chronic stage (29). We also highlighted that oral treatment with L-Arginine (L-Arg) led to the maintenance of renal NO bioavailability along with a reduction of AA toxicity (29, 66). Several studies have reported the impact of AA on endothelial cells in the literature. Shi and Feng showed that AA decreased cell viability in a dose- and time-dependent manner. They also demonstrated that AA could induce endothelial cell apoptosis and increase activation of caspase-3 (67). Guan et al. highlighted that HUVEC treated with AA display impaired angiogenesis capacities (68). More recently, our team showed a cytotoxic effect of AA on EAhy926 endothelial cells. In addition, exposure of aortic rings to AA impaired vascular relaxation to acetylcholine (69).

The Role of the Immune System

The histological examination of renal tissue samples from the first human cases had suggested that AAN was characterized by a diffuse and pauci-cellular interstitial fibrosis along with a corticomedullary gradient and marked tubular atrophy (12). The involvement of the immune system in AAN pathophysiology was rapidly evoked thanks to the results of a pilot clinical study in which steroids treatment resulted in slowing down the progression of the renal failure (70, 71). In addition, histopathological analyses from AAN patients highlighted the presence of an inflammatory infiltrate of mixed origin (monocytes/macrophages, B-lymphocytes and CD8 cytotoxic T-cell (72) or mastocytes (73), leading to a paradigm shift regarding the role of interstitial inflammation in AAN. Indeed, the role of the immune system has been largely demonstrated in both ischemic and other toxic AKI models (74).

In our AAN Wistar model, a significant inflammatory infiltrate following acute tubular necrosis has been described (27, 30). During the acute phase, injured PTEC secrete inflammatory cytokines contributing to the accumulation of inflammatory cells into the renal interstitium (increased urinary levels of MCP-1 on day 7 and of IL-1 α on day 10). During the chronic phase (day 35), a significant urinary release of IL-1 α , TNF- α , IFN- γ , MCP-1, IL-4, and TGF β was observed (27, 30). Moreover, an increased cortical expression of hyaluronan (HA) following tubular necrosis has been demonstrated in our AA-intoxicated mice as in other AKI models such as the IRI model (75–77). This ubiquitous glycosaminoglycan is normally found in the extracellular matrix of the renal medulla, but not the cortex, except during inflammation and ischemic injuries (76, 78). In inflammatory conditions, HA can be cleaved by hyaluronidases, generating low molecular weight “fragments” that interact with TLR2 and 4 (77, 79) thereby contributing to an inflammatory environment (76, 77, 79).

Following tubular necrosis and cytokines secretion, an inflammatory infiltrate including various immune cells such as dendritic cells (DC), neutrophils, macrophages, natural killer T-cells (NKT) and T and B lymphocytes has been described in AKI (74). The respective functions of these cells remain controversial, depending on the AKI model and the time course of the disease. Regarding experimental AAN, the role of the different

immune cell types was investigated only recently. Macrophages surrounding injured PTEC were observed in our AA-intoxicated rats and mice models (27, 29, 30). Phagocytosis of cell debris may lead to macrophage maturation (MHC class II expression) and stimulation of naive lymphocytes. The macrophage infiltrate was rapidly followed by a lymphocytic infiltrate composed of CD8⁺ and CD4⁺ T-cells (80). Using several depletion protocols (anti-CD4⁺, anti-CD8⁺ or anti-CD25⁺) in our AAN mouse model, we investigated the respective roles of these specific cells. We observed an aggravation of AA-induced AKI in mice depleted with anti-CD4⁺ or anti-CD8⁺ T-cells along with an increased *TNF-α* and *MCP-1* mRNA renal expression. However, regulatory T-cells depletion did not modify the severity of AKI, suggesting an independent mechanism (80). An increased proportion of myeloid CD11b^{high}F4/80^{mid} and a decreased proportion of their counterpart CD11b^{low}F4/80^{high} population was also observed after AA intoxication. After CD4⁺ T-cell depletion, the increase in the CD11b^{high}F4/80^{mid} population was even higher whereas the decrease in the CD11b^{low}F4/80^{high} population was more marked after CD8⁺ T-cell depletion. These results suggest that CD4⁺ and CD8⁺ T-cells are able to limit the severity of AA-induced AKI. The protective effect of CD4⁺ and CD8⁺ T-cells has been associated with an imbalance of the CD11b^{high}F4/80^{mid} and CD11b^{low}F4/80^{high} populations (80).

The Myofibroblasts

Tubulointerstitial fibrosis constitutes the final common pathway of CKD. In this regard, myofibroblasts are commonly pointed as the predominant effector cells of this process. They represent a unique population of cells that appears *de novo* after kidney injury due to the secretion of factors by injured tubules and inflammatory cells (31, 81). They exert their profibrotic function by producing the extracellular matrix, the crosslinking enzymes and the inhibitors of matrix degrading metalloproteinases (52). Expression of αSMA, a stress fiber protein that facilitates increased contractility, along with a typical fibroblastic morphology is their defining feature (52).

Given their pivotal importance, the cellular origin of those cells constitutes a critical question as well as an ongoing debate. The following cellular origins are proposed:

- Interstitial fibroblasts are commonly regarded as the most abundant progenitor to myofibroblasts (31).
- Proximal epithelial tubular cells (PTEC) were historically identified as a potential source of myofibroblasts. A process called epithelial-to-mesenchymal transition (EMT) was identified as an important mechanism responsible for the accumulation of interstitial myofibroblasts and collagen production during kidney fibrosis. Many *in vitro* studies have described the expression of mesenchymal markers when epithelial cells are injured. However, studies supporting the existence of EMT *in vivo* in the kidney have been much more limited and this hypothesis is nowadays considered as unlikely to occur *in vivo* (82). It is now proposed that expression of mesenchymal markers by epithelial cells *in vivo* should rather be interpreted as a sign of dedifferentiation (83).
- Endothelial cells (EC) have also been proposed as progenitors for myofibroblasts. A process called endothelial-to-mesenchymal transition (endo-MT) was described as a trans-differentiation of EC to a more mesenchymal phenotype. The magnitude of endo-MT contribution to the myofibroblast pool is variable depending on the experimental model used (52).
- Pericytes are specialized cells found in close vicinity to EC. Their role consists in maintaining vascular stability via cell-cell communication and by the release of factors such as TGFβ or VEGF (83). It is now proposed that renal pericytes could migrate from perivascular location to the interstitium and then acquire the phenotype of the myofibroblast. Nowadays, pericytes receive much interest since targeting these cells could lead to preservation of vascular network along with inhibition of fibrosis (83).
- Fibrocytes are circulating cells of myeloid lineage that are proposed to be the precursors of fibroblasts (83). These cells, deriving from the bone marrow, do not appear as major contributors to the pool of myofibroblasts in the kidney. It is rather proposed that they may act by paracrine signaling on other kidney cells to support and promote renal scarring (52, 83).

In experimental AAN, we have described that myofibroblasts as well as collagen accumulate in the interstitium following AA intoxication (**Figure 3**) (27, 29). In our Wistar rat model, we have highlighted the loss of the epithelial phenotype (N-cadherin and E-cadherin) along with the acquisition of mesenchymal cell markers (vimentin and αSMA) in PTEC during the acute phase of AAN (27). However, transmembrane migration was not observed leading to the conclusion that EMT was rather unlikely to occur. More recently, we showed that the early inhibition of the p-Smad2/3 signaling pathway by neutralizing anti-TGFβ antibody (1D11) improved renal function impairment and partially prevented epithelial-endothelial axis activation by reducing *platelet derived growth factor receptor β* (PDGFRβ)⁺ pericytes (84).

DISCUSSION

Considering the data collected from our initial Wistar rat model and our consecutive mouse models, we were able to relate simultaneous or successive events in relation with the four pivotal cellular responses proposed by Eddy (31) in order to link AKI to CKD mechanisms. The first insult resulting from AA intoxication is the onset of non-regenerative proximal tubular necrosis and early peritubular endothelial insult, resulting in a prominent interstitial influx by immunocompetent cells and hypoxia, respectively. Whatever the duration of AA intoxication (sustained to 35 days in our rat Wistar model or discontinued after 5 or 20 days in our mouse models), the inflammatory response is likely to be considered as the physiopathological link in the progression from the acute phase to the chronic phase, namely AKI-to-CKD transition. The promising attempts in blocking AA entry into PTEC or in modulating targeted subpopulations of immunocompetent cells




FIGURE 3 | Accumulation of α SMA-positive cells (**A–H**) and collagen I and III, highlighted by Sirius Red staining (**I–P**), within the interstitium of the kidney of CTL mice and mice intoxicated with AA (aristolochic acid I, Sigma-Aldrich, St. Louis, MO, USA) during 4 consecutive days. Mice were sacrificed 5, 10, and 20 days after first day of AA treatment [Magnification $\times 100$ for (**A–D**) and (**I–L**) and $\times 200$ for (**E–H**) and (**M–P**)].

are clearly attractive strategies to be more deeply investigated in the future in order to enhance recovery from AKI. Furthermore, the sustained impairment of the vascular network and the onset of myofibroblasts, a key cellular population in kidney disease progression, were also reported in our Wistar rat and mice AAN models.

Considering these “adaptive” AAN models as well as the four pivotal cellular responses to a toxic insult, interventional strategies could be interestingly explored, mimicking clinical situations. Indeed, there is no consensus available today regarding the definition of recovery from AKI. Several definitions exist such as those of Acute Dialysis Quality Initiative (ADQI), Kidney Disease: Improving Global Outcomes (KDIGO) and Acute Renal Failure Trial Network (ATN) and they are not unequivocal (85). There is increasing evidence suggesting that AKI and CKD should be considered as an interconnected syndrome (9). Clinical studies and experimental research strongly suggest that even after mild AKI and “apparent” recovery of renal function, clinical subjects or experimental animals are at increased risk of developing CKD (86). In our

opinion and according to those from other authors, this strongly suggests that there is no recovery *ad integrum* after AKI and that subclinical lesions (i.e., with normal plasma creatinine measurement) favor the onset of secondary CKD. It is likely that compensatory mechanisms exist such as “compensatory hypertrophy” of the remaining contralateral kidney after nephrectomy (in case of living kidney donor for instance). However, this mechanism cannot be considered as a recovery *ad integrum* even if the kidney function is seemingly normal. Moreover, it is now obvious that repeated “minor” episodes of AKI constitute a springboard to CKD. From that perspective, our AAN models differ from other classical AKI models such as ischemic reperfusion injury (IRI), unilateral ureteral obstruction (UUO), 5/6e nephrectomy model and nephrotoxic AKI models such as ciclosporin, cisplatin, and adriamycin. Indeed, the toxic insult due to multiple AA injections, even if mild, is sustained in time. Therefore, tubular regeneration is dampened, repair is maladaptive especially in the context of DNA damage and severe reduction of peritubular capillaries leading ultimately to tubular atrophy, interstitial chronic inflammation, vascular

rarefaction and prominent fibrosis. Each model suffers from technical difficulties and limitations regarding extrapolation to clinical situations. However, we actually would like to underline some advantages of our AAN models: they do not require any particular skills by opposition to surgical models, the toxicity is rapidly induced and it generates homogenous alterations in both kidneys; moreover, contrasting with UUO or unilateral IRI, there is no renal compensation from the other kidney; finally, there is prominent fibrosis in the chronic phases of the model. Despite numerous advantages of the AAN models, it should be mentioned that the genotoxic properties of AA could represent a limitation of the AAN models—but only in chronic exposure (at least more than 3 months in our hands). Indeed, AA have been recognized for many years as a human carcinogen causing upper urinary tract carcinoma but also bladder cancer and renal cell carcinoma (18). Exposure of rodents to AA could interfere with cell cycle of the urothelium or the digestive tract and induce activation of protooncogenes such as H-ras. In rodents, H-ras has been found to play the same role as TP53 (14).

CONCLUSIONS

The incidence and prevalence of CKD are still rising worldwide (87, 88). It has become increasingly clear that AKI constitutes a significant risk factor for the development of CKD (9). In this regard, animal models play a crucial role in unraveling the pathological mechanisms of the so-called AKI-to-CKD

transition (10). On the basis of our findings as well as data from the literature, we were able to observe a biphasic evolution of the structure and function parameters following AA intoxication with tubular injury which constitutes the first pivotal cellular event. Following PTEC injury, inflammation was described as persisting all along the experimental protocols. We propose that the inflammatory response constitutes the link in the progression from the acute phase to the chronic phase. The prolonged inflammatory response hampered tubular regeneration and ultimately led to tubular atrophy, interstitial chronic inflammation, peritubular capillaries rarefaction and prominent fibrosis. Finally, impairment of the vascular network and myofibroblasts, a key cellular population in kidney disease progression, were also described in our AAN rodent models. In conclusion, these models recapitulate the four pivotal cellular responses that are crucial in the AKI-to-CKD transition.

AUTHOR CONTRIBUTIONS

BT and JI wrote together the manuscript and prepared the figures. DA-E, AM-H, BO, DE, PA, and HC reviewed the draft and contributed to its improvement. CJ-M, CN, and JN supervised each step of the process, including the selection of the bibliographical references. All authors contributed to the article and approved the submitted version.

REFERENCES

- Liano F, Felipe C, Tenorio MT, Rivera M, Abaira V, Saez-de-Urturi JM, et al. Long-term outcome of acute tubular necrosis: a contribution to its natural history. *Kidney Int.* (2007) 71:679–86. doi: 10.1038/sj.ki.5002086
- Kjellstrand CM, Ebben J, Davin T. Time of death, recovery of renal function, development of chronic renal failure and need for chronic hemodialysis in patients with acute tubular necrosis. *Trans Am Soc Artif Intern Organs.* (1981) 27:45–50.
- Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al. Acute kidney injury increases risk of ESRD among elderly. *J Am Soc Nephrol.* (2009) 20:223–8. doi: 10.1681/ASN.2007080837
- Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordonez JD, et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. *Kidney Int.* (2009) 76:893–9. doi: 10.1038/ki.2009.289
- Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE. Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. *Kidney Int.* (2009) 76:1089–97. doi: 10.1038/ki.2009.332
- Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. *JAMA.* (2009) 302:1179–85. doi: 10.1001/jama.2009.1322
- Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. *JAMA.* (2003) 290:1360–70. doi: 10.1001/jama.290.10.1360
- Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. *Kidney Int.* (2011) 79:1361–9. doi: 10.1038/ki.2011.42
- Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. *N Engl J Med.* (2014) 371:58–66. doi: 10.1056/NEJMra1214243
- Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z. Rodent models of AKI-CKD transition. *Am J Physiol Renal Physiol.* (2018) 315:F1098–106. doi: 10.1152/ajprenal.00199.2018
- Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. *Lancet.* (1993) 341:387–91. doi: 10.1016/0140-6736(93)92984-2
- Depierreux M, Van Damme B, Vanden Houte K, Vanherweghem JL. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. *Am J Kidney Dis.* (1994) 24:172–80. doi: 10.1016/S0272-6386(12)80178-8
- Schmeiser HH, Schoepe KB, Wiessler M. DNA adduct formation of aristolochic acid I and II *in vitro* and *in vivo*. *Carcinogenesis.* (1988) 9:297–303. doi: 10.1093/carcin/9.2.297
- Schmeiser HH, Janssen JW, Lyons J, Scherf HR, Pfau W, Buchmann A, et al. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. *Cancer Res.* (1990) 50:5464–9.
- Schmeiser HH, Scherf HR, Wiessler M. Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. *Cancer Lett.* (1991) 59:139–43. doi: 10.1016/0304-3835(91)90178-K
- Arlt VM, Schmeiser HH, Pfeifer GP. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. *Carcinogenesis.* (2001) 22:133–40. doi: 10.1093/carcin/22.1.133
- Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, et al. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. *Am J Kidney Dis.* (2004) 43:e11–7. doi: 10.1053/j.ajkd.2003.11.024
- Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use

- of a Chinese herb (*Aristolochia fangchi*). *N Engl J Med*. (2000) 342:1686–92. doi: 10.1056/NEJM200006083422301
19. Stiborova M, Arlt VM, Schmeiser HH. Balkan endemic nephropathy: an update on its aetiology. *Arch Toxicol*. (2016) 90:2595–615. doi: 10.1007/s00204-016-1819-3
 20. Jelaković B, Dika Ž, Arlt VM, Stiborova M, Pavlović NM, Nikolić J, et al. Balkan endemic nephropathy and the causative role of aristolochic acid. *Semin Nephrol*. (2019) 39:284–96. doi: 10.1016/j.semnephrol.2019.02.007
 21. Hsieh SC, Lin IH, Tseng WL, Lee CH, Wang JD. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. *Chin Med*. (2008) 3:13. doi: 10.1186/1749-8546-3-13
 22. Grollman AP. Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. *Environ Mol Mutagen*. (2013) 54:1–7. doi: 10.1002/em.21756
 23. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. *Kidney Int*. (2008) 74:158–69. doi: 10.1038/ki.2008.129
 24. Jadot I, Declèves AE, Nortier J, Caron N. An integrated view of aristolochic acid nephropathy: update of the literature. *Int J Mol Sci*. (2017) 18:297. doi: 10.3390/ijms18020297
 25. Cosyns JP, Dehoux JB, Guiot Y, Goebbels RM, Robert A, Bernard AM, et al. Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? *Kidney Int*. (2001) 59:2164–73. doi: 10.1046/j.1523-1755.2001.00731.x
 26. Lebeau C, Debelle FD, Arlt VM, Pozdzik A, De Prez EG, Phillips DH, et al. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. *Nephrol Dial Transplant*. (2005) 20:2321–32. doi: 10.1093/ndt/gfn042
 27. Pozdzik AA, Salmon IJ, Debelle FD, Decaestecker C, Van den Branden C, Verbeelen D, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. *Kidney Int*. (2008) 73:595–607. doi: 10.1038/sj.ki.5002714
 28. Baudoux TE, Pozdzik AA, Arlt VM, De Prez EG, Antoine MH, Quillard N, et al. Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. *Kidney Int*. (2012) 82:1105–13. doi: 10.1038/ki.2012.264
 29. Jadot I, Colombaro V, Martin B, Habsch I, Botton O, Nortier J, et al. Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy. *PLoS ONE*. (2017) 12:e0183604. doi: 10.1371/journal.pone.0183604
 30. Pozdzik AA, Salmon IJ, Husson CP, Decaestecker C, Rogier E, Bourgeade MF, et al. Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy. *Nephrol Dial Transplant*. (2008) 23:2480–91. doi: 10.1093/ndt/gfn140
 31. Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. *Kidney Int*. (2014) 4:S2–8. doi: 10.1038/kisup.2014.2
 32. Bakhiya N, Arlt VM, Bahn A, Burckhardt G, Phillips DH, Glatt H. Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. *Toxicology*. (2009) 264:74–9. doi: 10.1016/j.tox.2009.07.014
 33. Babu E, Takeda M, Nishida R, Noshiro-Kofuji R, Yoshida M, Ueda S, et al. Interactions of human organic anion transporters with aristolochic acids. *J Pharmacol Sci*. (2010) 113:192–6. doi: 10.1254/jphs.09339SC
 34. Xue X, Gong LK, Maeda K, Luan Y, Qi XM, Sugiyama Y, et al. Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. *Mol Pharm*. (2011) 8:2183–92. doi: 10.1021/mp100418u
 35. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP. Selective toxicity of aristolochic acids I and II. *Drug Metab Dispos*. (2007) 35:1217–22. doi: 10.1124/dmd.107.014688
 36. Nortier JL, Schmeiser HH, Muniz Martinez MC, Arlt VM, Vervaeke C, Garbar CH, et al. Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure. *Nephrol Dial Transplant*. (2003) 18:426–8. doi: 10.1093/ndt/18.2.426
 37. Hsin YH, Cheng CH, Tzen JT, Wu MJ, Shu KH, Chen HC. Effect of aristolochic acid on intracellular calcium concentration and its links with apoptosis in renal tubular cells. *Apoptosis*. (2006) 11:2167–77. doi: 10.1007/s10495-006-0289-0
 38. Zhu S, Wang Y, Jin J, Guan C, Li M, Xi C, et al. Endoplasmic reticulum stress mediates aristolochic acid I-induced apoptosis in human renal proximal tubular epithelial cells. *Toxicol In Vitro*. (2012) 26:663–71. doi: 10.1016/j.tiv.2012.03.005
 39. Qi X, Cai Y, Gong L, Liu L, Chen F, Xiao Y, et al. Role of mitochondrial permeability transition in human renal tubular epithelial cell death induced by aristolochic acid. *Toxicol Appl Pharmacol*. (2007) 222:105–10. doi: 10.1016/j.taap.2007.03.029
 40. Yu FY, Wu TS, Chen TW, Liu BH. Aristolochic acid I induced oxidative DNA damage associated with glutathione depletion and ERK1/2 activation in human cells. *Toxicol In Vitro*. (2011) 25:810–6. doi: 10.1016/j.tiv.2011.01.016
 41. Li YC, Tsai SH, Chen SM, Chang YM, Huang TC, Huang YP, et al. Aristolochic acid-induced accumulation of methylglyoxal and Nepsilon-(carboxymethyl)lysine: an important and novel pathway in the pathogenic mechanism for aristolochic acid nephropathy. *Biochem Biophys Res Commun*. (2012) 423:832–7. doi: 10.1016/j.bbrc.2012.06.049
 42. Chen B, Bai Y, Sun M, Ni X, Yang Y, Yang Y, et al. Glutathione S-transferases T1 null genotype is associated with susceptibility to aristolochic acid nephropathy. *Int Urol Nephrol*. (2012) 44:301–7. doi: 10.1007/s11255-011-0082-z
 43. Chen YY, Chung JG, Wu HC, Bau DT, Wu KY, Kao ST, et al. Aristolochic acid suppresses DNA repair and triggers oxidative DNA damage in human kidney proximal tubular cells. *Oncol Rep*. (2010) 24:141–53. doi: 10.3892/or.00000839
 44. Romanov V, Whyard TC, Waltzer WC, Grollman AP, Rosenquist T. Aristolochic acid-induced apoptosis and G2 cell cycle arrest depends on ROS generation and MAP kinases activation. *Arch Toxicol*. (2015) 89:47–56. doi: 10.1007/s00204-014-1249-z
 45. Kurts C, Panzer U, Anders HJ, Rees AJ. The immune system and kidney disease: basic concepts and clinical implications. *Nat Rev Immunol*. (2013) 13:738–53. doi: 10.1038/nri3523
 46. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. *Nat Med*. (2010) 16:535–43. doi: 10.1038/nm.2144
 47. Bonventre JV. Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis. *Kidney Int*. (2014) 4:S39–44. doi: 10.1038/kisup.2014.8
 48. Dagher PC, Mai EM, Hato T, Lee SY, Anderson MD, Karozos SC, et al. The p53 inhibitor pifithrin-alpha can stimulate fibrosis in a rat model of ischemic acute kidney injury. *Am J Physiol Renal Physiol*. (2012) 302:F284–91. doi: 10.1152/ajprenal.00317.2011
 49. Ying Y, Kim J, Westphal SN, Long KE, Padanilam BJ. Targeted deletion of p53 in the proximal tubule prevents ischemic renal injury. *J Am Soc Nephrol*. (2014) 25:2707–16. doi: 10.1681/ASN.2013121270
 50. Sborchia M, De Prez EG, Antoine MH, Bienfait L, Indra R, Valbuena G, et al. The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage *in vivo* and *in vitro*. *Arch Toxicol*. (2019) 93:3345–66. doi: 10.1007/s00204-019-02578-4
 51. Duquesne M, Declèves AE, De Prez E, Nortier J, Colet JM. Interest of metabonomic approach in environmental nephrotoxicants: application to aristolochic acid exposure. *Food Chem Toxicol*. (2017) 108(Pt. A):19–29. doi: 10.1016/j.fct.2017.07.015
 52. Falke LL, Gholizadeh S, Goldschmeding R, Kok RJ, Nguyen TQ. Diverse origins of the myofibroblast-implications for kidney fibrosis. *Nat Rev Nephrol*. (2015) 11:233–44. doi: 10.1038/nrneph.2014.246
 53. Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. *Compr Physiol*. (2012) 2:1303–53. doi: 10.1002/cphy.c110041
 54. Guerrot D, Dussaule JC, Kavvadas P, Boffa JJ, Chadichristos CE, Chatziantoniou C. Progression of renal fibrosis: the underestimated role of endothelial alterations. *Fibrogenesis Tissue Repair*. (2012) 5(Suppl. 1):S15. doi: 10.1186/1755-1536-5-S1-S15
 55. Zuk A, Bonventre JV. Acute kidney injury. *Annu Rev Med*. (2016) 67:293–307. doi: 10.1146/annurev-med-050214-013407
 56. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. *Clin Chim Acta*. (2010) 411:1412–20. doi: 10.1016/j.cca.2010.06.019
 57. Afsar B, Afsar RE, Dagal T, Kaya E, Erus S, Ortiz A, et al. Capillary rarefaction from the kidney point of view. *Clin Kidney J*. (2018) 11:295–301. doi: 10.1093/ckj/sfx133
 58. Baylis C. Nitric oxide deficiency in chronic kidney disease. *Am J Physiol Renal Physiol*. (2008) 294:F1–9. doi: 10.1152/ajprenal.00424.2007

59. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progression in chronic kidney disease. *Am J Physiol Renal Physiol.* (2010) 298:F1078–94. doi: 10.1152/ajprenal.00017.2010
60. Long DA, Norman JT, Fine LG. Restoring the renal microvasculature to treat chronic kidney disease. *Nat Rev Nephrol.* (2012) 8:244–50. doi: 10.1038/nrneph.2011.219
61. Molitoris BA. Therapeutic translation in acute kidney injury: the epithelial/endothelial axis. *J Clin Invest.* (2014) 124:2355–63. doi: 10.1172/JCI72269
62. Basile DP, Friedrich JL, Spahic J, Knipe N, Mang H, Leonard EC, et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. *Am J Physiol Renal Physiol.* (2011) 300:F721–33. doi: 10.1152/ajprenal.00546.2010
63. Sun D, Feng J, Dai C, Sun L, Jin T, Ma J, et al. Role of peritubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy. *Am J Nephrol.* (2006) 26:363–71. doi: 10.1159/000094778
64. Yang L, Li X, Wang H. Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. *Nephrol Dial Transplant.* (2007) 22:445–56. doi: 10.1093/ndt/gfl556
65. Wen YJ, Qu L, Li XM. Ischemic injury underlies the pathogenesis of aristolochic acid-induced acute kidney injury. *Transl Res.* (2008) 152:38–46. doi: 10.1016/j.trsl.2008.05.002
66. Declèves AE, Jadot I, Colombaro V, Martin B, Voisin V, Nortier J, et al. Protective effect of nitric oxide in aristolochic acid-induced toxic acute kidney injury: an old friend with new assets. *Exp Physiol.* (2016) 101:193–206. doi: 10.1113/EP085333
67. Shi H, Feng JM. Aristolochic acid induces apoptosis of human umbilical vein endothelial cells *in vitro* by suppressing PI3K/Akt signaling pathway. *Acta Pharmacol Sin.* (2011) 32:1025–30. doi: 10.1038/aps.2011.74
68. Guan T, Huang K, Liu Y, Hou S, Hu C, Li Y, et al. Aristolochic acid inhibits Slit2-induced migration and tube formation via inactivation of Robo1/Robo2-NCK1/NCK2 signaling pathway in human umbilical vein endothelial cells. *Toxicol Lett.* (2019) 300:51–8. doi: 10.1016/j.toxlet.2018.10.022
69. Youl ENH, Husson C, El Khattabi C, El Mere S, Declèves AE, Pochet S, et al. Characterization of cytotoxic effects of aristolochic acids on the vascular endothelium. *Toxicol In Vitro.* (2020) 65:104811. doi: 10.1016/j.tiv.2020.104811
70. Vanherweghem JL, Abramowicz D, Tielemans C, Depierreux M. Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy. *Am J Kidney Dis.* (1996) 27:209–15. doi: 10.1016/S0272-6386(96)90542-9
71. Martinez MC, Nortier J, Vereerstraeten P, Vanherweghem JL. Steroid therapy in chronic interstitial renal fibrosis: the case of Chinese-herb nephropathy. *Nephrol Dial Transplant.* (2002) 17:2033–4. doi: 10.1093/ndt/17.11.2033-a
72. Pozdzik AA, Berton A, Schmeiser HH, Missoum W, Decaestecker C, Salmon IJ, et al. Aristolochic acid nephropathy revisited: a place for innate and adaptive immunity? *Histopathology.* (2010) 56:449–63. doi: 10.1111/j.1365-2559.2010.03509.x
73. Wu Y, Liu Z, Hu W, Li L. Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy. *Hum Exp Toxicol.* (2005) 24:41–7. doi: 10.1191/0960327105ht502oa
74. Jang HR, Rabb H. Immune cells in experimental acute kidney injury. *Nat Rev Nephrol.* (2015) 11:88–101. doi: 10.1038/nrneph.2014.180
75. Declèves A E, Pozdzik A, Baudoux T, Habsch I, De Prez E, Flamion B, et al. CD44 positive cells and hyaluronan are a hallmark of a rat model of aristolochic acid nephropathy. *J Cytol Histol.* (2013) 4:156. doi: 10.4172/2157-7099.1000186
76. Declèves AE, Caron N, Voisin V, Legrand A, Bouby N, Kultti A, et al. Synthesis and fragmentation of hyaluronan in renal ischaemia. *Nephrol Dial Transplant.* (2012) 27:3771–81. doi: 10.1093/ndt/gfs098
77. Shirali AC, Goldstein DR. Tracking the toll of kidney disease. *J Am Soc Nephrol.* (2008) 19:1444–50. doi: 10.1681/ASN.2008010123
78. Declèves AE, Caron N, Nonclercq D, Legrand A, Toubeau G, Kramp R, et al. Dynamics of hyaluronan, CD44, and inflammatory cells in the rat kidney after ischemia/reperfusion injury. *Int J Mol Med.* (2006) 18:83–94. doi: 10.3892/ijmm.18.1.83
79. Anders HJ, Schaefer L. Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. *J Am Soc Nephrol.* (2014) 25:1387–400. doi: 10.1681/ASN.2014010117
80. Baudoux T, Husson C, De Prez E, Jadot I, Antoine MH, Nortier JL, et al. CD4(+) and CD8(+) T cells exert regulatory properties during experimental acute aristolochic acid nephropathy. *Sci Rep.* (2018) 8:5334. doi: 10.1038/s41598-018-23565-2
81. Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. *J Am Soc Nephrol.* (2015) 26:1765–76. doi: 10.1681/ASN.2015010006
82. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? *J Clin Invest.* (2011) 121:468–74. doi: 10.1172/JCI44595
83. Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. *Nat Rev Nephrol.* (2015) 11:264–76. doi: 10.1038/nrneph.2015.3
84. Pozdzik AA, Giordano L, Li G, Antoine MH, Quillard N, Godet J, et al. Blocking TGF- β signaling pathway preserves mitochondrial proteostasis and reduces early activation of PDGFR β + pericytes in aristolochic acid induced acute kidney injury in wistar male rats. *PLoS ONE.* (2016) 11:e0157288. doi: 10.1371/journal.pone.0157288
85. Kellum JA. How can we define recovery after acute kidney injury? Considerations from epidemiology and clinical trial design. *Nephron Clin Pract.* (2014) 127:81–8. doi: 10.1159/000363681
86. Legouis D, Galichon P, Bataille A, Chevret S, Provenchère S, Boutten A, et al. Rapid occurrence of chronic kidney disease in patients experiencing reversible acute kidney injury after cardiac surgery. *Anesthesiology.* (2017) 126:39–46. doi: 10.1097/ALN.0000000000001400
87. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. *Kidney Int.* (2015) 88:950–7. doi: 10.1038/ki.2015.230
88. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. *Lancet.* (2013) 382:260–72. doi: 10.1016/S0140-6736(13)60687-X

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Baudoux, Jadot, Declèves, Antoine, Colet, Botton, De Prez, Pozdzik, Husson, Caron and Nortier. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.